標(biāo)題: Titlebook: Endocrine Disorders in Kidney Disease; Diagnosis and Treatm Connie M. Rhee,Kamyar Kalantar-Zadeh,Gregory A. Br Book 2019 Springer Nature Sw [打印本頁(yè)] 作者: BOUT 時(shí)間: 2025-3-21 19:41
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease影響因子(影響力)
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease被引頻次
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease被引頻次學(xué)科排名
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease年度引用
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease年度引用學(xué)科排名
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease讀者反饋
書(shū)目名稱(chēng)Endocrine Disorders in Kidney Disease讀者反饋學(xué)科排名
作者: Meditative 時(shí)間: 2025-3-21 21:43
Introduction: A Vibrant HybridityThis chapter will focus on the pharmacologic interventions for treatment of dyslipidemia in patients with chronic kidney disease (CKD). Herein, we will discuss drugs of interest for lipid management and their current and potential future use in CKD patients.作者: 延期 時(shí)間: 2025-3-22 03:51
Drugs for Treatment of Dyslipidemia Available in the?USAThis chapter will focus on the pharmacologic interventions for treatment of dyslipidemia in patients with chronic kidney disease (CKD). Herein, we will discuss drugs of interest for lipid management and their current and potential future use in CKD patients.作者: Mucosa 時(shí)間: 2025-3-22 04:32
Connie M. Rhee,Kamyar Kalantar-Zadeh,Gregory A. BrCovers common endocrine disorders and their impact on chronic kidney disease.Provides diagnostic guidance and a range of treatment considerations.Invaluable resource for physicians, residents, fellows作者: FLASK 時(shí)間: 2025-3-22 12:33
http://image.papertrans.cn/e/image/309705.jpg作者: 欄桿 時(shí)間: 2025-3-22 14:10 作者: 欄桿 時(shí)間: 2025-3-22 19:53
https://doi.org/10.1007/978-3-658-08894-1r cardiovascular and kidney disease. In this context, there has been increasing interest in the impact of insulin resistance and the compensatory hyperinsulinemia on kidney disease, independent to that of the contribution of overt diabetes to the development of kidney disease. It is unknown whether 作者: GLIB 時(shí)間: 2025-3-22 21:49 作者: 整潔 時(shí)間: 2025-3-23 01:58
https://doi.org/10.1057/9780230625310ion. While diabetes is one of the most important causes of chronic kidney disease, the gradual decline in kidney function itself causes significant changes that alter glucose homeostasis in patients with kidney disease. In many patients with diabetic nephropathy requiring dialysis, glycemic control 作者: adduction 時(shí)間: 2025-3-23 06:37
Relocation of Economic Activityabetic kidney disease (DKD) remain controversial. A variety of factors associated with kidney disease and/or the uremic state can impact the accuracy and interpretability of currently available glycemic measures. Alterations in erythrocyte survival time, hemoglobin concentrations, and other factors 作者: Abnormal 時(shí)間: 2025-3-23 09:52 作者: 扔掉掐死你 時(shí)間: 2025-3-23 17:15 作者: exacerbate 時(shí)間: 2025-3-23 20:40 作者: Cupping 時(shí)間: 2025-3-23 23:03 作者: 熱烈的歡迎 時(shí)間: 2025-3-24 06:05
Elena Allegri,Barbara Rosina,Mara Sanfelici axis contribute to testicular dysfunction and low testosterone levels in CKD. Testosterone levels decline as CKD progresses with further reductions in the estimated glomerular filtration rate (eGFR). Both CKD and low serum total testosterone concentrations are independent predictors of mortality ri作者: 清澈 時(shí)間: 2025-3-24 06:40
https://doi.org/10.1007/978-981-13-3350-7CKD). Despite the fact that kidney disease affects approximately one out of ten women in the United States and one out of five women over the age of 60?years, women’s health issues in the setting of CKD remain one of the most neglected and under-recognized issues in clinical practice. While the exac作者: FLAX 時(shí)間: 2025-3-24 13:18 作者: Largess 時(shí)間: 2025-3-24 16:10
Palesa R. Sekhejane,Thabang S. Dladlanited States. From this astonishing number, roughly 450,000 patients have end-stage renal disease (ESRD) requiring weekly/daily renal replacement therapy. Furthermore, given the prevalence of the causes of CKD, it is expected that the number of patients with ESRD will increase to more than 750,000 b作者: ANTI 時(shí)間: 2025-3-24 21:54 作者: AVID 時(shí)間: 2025-3-25 00:10
understanding of the impact of endocrine disorders on kidney disease .patients., the ability to identify persistent gaps in knowledge for future investigation, and?.move. closer?.towards. the goal of improving the health and survival of .the.?chronic kidney disease .population.. ..?.978-3-319-97765-2作者: 表示向下 時(shí)間: 2025-3-25 06:11 作者: Feigned 時(shí)間: 2025-3-25 08:55 作者: 浪費(fèi)時(shí)間 時(shí)間: 2025-3-25 14:03
Relocation of Economic Activityhip between A1C and mortality, with current epidemiological data suggesting that relatively conservative A1C targets may be desirable. Patients with DKD are additionally known to be at particular risk for hypoglycemia, and hypoglycemia avoidance is an important priority when establishing glycemic ta作者: 定點(diǎn) 時(shí)間: 2025-3-25 18:49
,Conclusion: Reluctance’s “Other”,acokinetics are altered again with increased drug and urea clearance. As a result, treatment of diabetes in CKD requires frequent reassessment to meet the patient’s changing drug response and needs..This chapter reviews the specific pharmacokinetic and dosing considerations of each antihyperglycemic作者: 盡管 時(shí)間: 2025-3-25 21:42 作者: Fibrillation 時(shí)間: 2025-3-26 04:01 作者: excrete 時(shí)間: 2025-3-26 05:37 作者: 漫步 時(shí)間: 2025-3-26 10:31 作者: Melanocytes 時(shí)間: 2025-3-26 13:42 作者: 煩人 時(shí)間: 2025-3-26 20:20 作者: 虛度 時(shí)間: 2025-3-26 21:42
Glucose Homeostasis and the Burnt-Out Diabetes Phenomenon in Patients with Kidney Diseasertality. Glycemic control that is tailored to hemodialysis patients and glycemic control that differs from that of non-dialysis patients are needed to avoid hemodialysis-induced hypoglycemia and other glycemic disarrays.作者: GENUS 時(shí)間: 2025-3-27 02:03
Glycemic Metrics and Targets in Kidney Diseasehip between A1C and mortality, with current epidemiological data suggesting that relatively conservative A1C targets may be desirable. Patients with DKD are additionally known to be at particular risk for hypoglycemia, and hypoglycemia avoidance is an important priority when establishing glycemic ta作者: 誘導(dǎo) 時(shí)間: 2025-3-27 06:49 作者: 寒冷 時(shí)間: 2025-3-27 13:11 作者: 不連貫 時(shí)間: 2025-3-27 15:45 作者: 就職 時(shí)間: 2025-3-27 21:00 作者: peptic-ulcer 時(shí)間: 2025-3-28 01:54
Pregnancy in Kidney Diseased no significant increases in maternal mortality. Improved management of comorbidities such as hypertension, intensified dialysis in women with ESKD, and close to attention to management of CKD-associated complications such as volume control and nutrition, anemia, and mineral-bone disease factors is作者: 拋媚眼 時(shí)間: 2025-3-28 04:25
Lipid Disorders Associated with Chronic Kidney Disease and Nephrotic Syndromen profile. These abnormalities can play a substantial role in pathogenesis and progression of renal and cardiovascular disease in this population. There are many different factors which can impact lipid metabolism and contribute to the nature of lipid abnormalities observed in patients with kidney d作者: Sputum 時(shí)間: 2025-3-28 08:19 作者: 樂(lè)章 時(shí)間: 2025-3-28 12:57
Thyroid Status and Outcomes in Kidney Diseasein dialysis patients, possibly due to overlap of its accompanying signs and symptoms with those of uremia (e.g., fatigue, depression, reduced cognition, impaired physical function), as well as attribution of thyroid function test changes to underlying illness rather than primary thyroid disease [1, 2].作者: boisterous 時(shí)間: 2025-3-28 16:02 作者: 紳士 時(shí)間: 2025-3-28 20:03 作者: OCTO 時(shí)間: 2025-3-29 00:13
Shark Skin: Taking a Bite Out of Bacteria,ir effects on the gastrointestinal tract, kidney, and bone in order to maintain normal levels of calcium. Hypercalcemia and hypocalcemia indicate critical disruptions of calcium homeostasis. This chapter reviews the regulation of calcium homeostasis and the diagnosis and management of disorders of calcium metabolism.作者: 刺耳的聲音 時(shí)間: 2025-3-29 06:43 作者: 格子架 時(shí)間: 2025-3-29 09:50 作者: 窗簾等 時(shí)間: 2025-3-29 12:57 作者: 跳動(dòng) 時(shí)間: 2025-3-29 17:53 作者: lattice 時(shí)間: 2025-3-29 20:44 作者: 有效 時(shí)間: 2025-3-30 01:52 作者: 慷慨援助 時(shí)間: 2025-3-30 06:32 作者: 橡子 時(shí)間: 2025-3-30 11:23 作者: 黃油沒(méi)有 時(shí)間: 2025-3-30 12:35 作者: SNEER 時(shí)間: 2025-3-30 17:04
Glycemic Metrics and Targets in Kidney Diseaseabetic kidney disease (DKD) remain controversial. A variety of factors associated with kidney disease and/or the uremic state can impact the accuracy and interpretability of currently available glycemic measures. Alterations in erythrocyte survival time, hemoglobin concentrations, and other factors 作者: Cumulus 時(shí)間: 2025-3-30 20:50
